Cancer Communications (Feb 2021)
High‐throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion
- Zhengbo Song,
- Chunwei Xu,
- Xingxiang Pu,
- Youcai Zhu,
- Wenxian Wang,
- Xingliang Li,
- Yanqiu Gao,
- Wenliang Zhu,
- Yunwei He,
- Lin Wu,
- Li Mao,
- Li Chen,
- Ming Chen
Affiliations
- Zhengbo Song
- Department of Medical Oncology Institute of Cancer and Basic Medicine Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou Zhejiang 310002 P. R. China
- Chunwei Xu
- Department of Pathology Fujian Cancer Hospital Fuzhou Fujian 350014 P. R. China
- Xingxiang Pu
- Department of Thoracic Oncology Hunan Cancer Hospital Changsha Hunan 410013 P. R. China
- Youcai Zhu
- Thoracic Disease Diagnosis and Treatment Center Zhejiang Rongjun Hospital Jiaxing Zhejiang 314000 P. R. China
- Wenxian Wang
- Department of Medical Oncology Institute of Cancer and Basic Medicine Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou Zhejiang 310002 P. R. China
- Xingliang Li
- Tumor Molecular Laboratory Zhejiang Rongjun Hospital Jiaxing Zhejiang 314000 P. R. China
- Yanqiu Gao
- HeliTec Biotechnologies Shenzhen Guangdong 518000 P. R. China
- Wenliang Zhu
- HeliTec Biotechnologies Shenzhen Guangdong 518000 P. R. China
- Yunwei He
- HeliTec Biotechnologies Shenzhen Guangdong 518000 P. R. China
- Lin Wu
- Department of Thoracic Oncology Hunan Cancer Hospital Changsha Hunan 410013 P. R. China
- Li Mao
- Betta Pharmaceutical Hangzhou Zhejiang 311100 P. R. China
- Li Chen
- HeliTec Biotechnologies Shenzhen Guangdong 518000 P. R. China
- Ming Chen
- Department of Radiotherapy Institute of Cancer and Basic Medicine Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou Zhejiang 310022 P. R. China
- DOI
- https://doi.org/10.1002/cac2.12133
- Journal volume & issue
-
Vol. 41,
no. 2
pp. 192 – 196
Abstract
No abstracts available.
